ArticleJournal of bone oncology2026
Risk of fracture among lung cancer survivors by cancer treatment modality: A population-based retrospective cohort study.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evidence on fracture incidence among lung cancer (LC) survivors remains limited. We assessed fracture risk in LC survivors who underwent curative-intent surgery, stratified by treatment modality and postoperative time. Methods: This retrospective, population-based cohort study used the Korean National Health Insurance Service database (2009-2022), including LC survivors ( Results: LC survivors had an elevated risk of fracture compared with non-cancer controls across the overall follow-up period. Vertebral fracture risk was most pronounced within the first year after surgery (cause-specific hazard ratios [csHRs] 1.81, 95% confidence interval [CI] 1.45-2.26). Hip fracture risk within the first year was similarly directed but did not reach significance in the overall cohort (csHR 1.40, 95% CI 0.98-1.98), whereas it was significantly elevated in the screening subgroup after additional adjustment for health behaviors and body mass index (csHR 1.83, 95% CI 1.11-4.43). During the overall follow-up period, the risk of any fracture was elevated among LC survivors who received chemotherapy (csHR 1.32, 95% CI 1.21-1.45), radiation therapy (csHR 1.78, 95% CI 1.43-2.23), or chemoradiotherapy (csHR 1.73, 95% CI 1.50-1.99), compared with controls. Conclusion: Compared with non-cancer controls, LC survivors had a generally higher risk of fracture at various sites, which varied by time since surgery and by cancer treatment modality. These findings suggest that osteoporosis screening and multimodal fracture prevention strategies should be considered for LC survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.